Introduction
The polyomavirus family consists of different viral strains, among which the BK-, JC-, and the SV-40 strains are pathogenic in humans. Polyomaviruses are double stranded, nonencapsulated DNA viruses of approximately 5300 base pairs with substantial gene homology (approximately 70% between BK-and JC-viruses). They are tropic for certain cell types (BK-and JC-viruses for renal tubular and transitional cells) and require immune modulation and host cell activation for replication. This feature may help to explain compartment-specific disease processes, such as BK-virus-associated hemorrhagic cystitis after bladder injury in the setting of bone marrow transplantation (and not BK-virus nephropathy, BKN), versus BKN after kidney transplantation and tubular injury (and generally not hemorrhagic cystitis). Polyomaviruses adhere to their specific host cells through binding of viral capsid proteins (likely in the VP-1 region) to cell surface receptors; BK-viruses likely bind to N-linked glycoproteins containing a (2,3)-linked sialic acids/gangliosides GD1b and GT1b [1, 2] . After cell entry via caveola-mediated endocytosis, the BK-viruses migrate through the cytoplasm/endoplasmatic reticulum/microtubules and the nuclear pores into the host cell nucleus, where viral transcription, replication, and assembly take place [2] [3] [4] [5] . Ultimately, host cells are lysed and mature daughter virions released.
Polyomaviruses are ubiquitous and have specifically adapted to their hosts during evolution. They are of no clinical significance in immune competent individuals. It is important to remember that the viruses are often not cleared from the body after a primary infection, which occurs with 'flu-like symptoms' early in life. Rather, it is assumed that primary entry of BK-or JC-viruses (SV-40 viruses do not play a significant clinical role) into the host results in transient viremia and viral spread to permissive cells, in particular, transitional and renal tubular epithelial cells, where the viruses establish life-long latency under normal cellular and humoral immune-surveillance [6] [7] [8] [9] . Latent polyomavirus infections cannot be identified histologically or immunohistochemically but rather require molecular techniques for detection (Southern blot or PCR analyses) [6, 8] .
Disease caused by the re-activation of latent polyomaviruses is typically not seen in the immunecompetent host. Slight changes in the immune status (during pregnancy, in patients suffering from diabetes mellitus, or in 'healthy' individuals including stable renal allograft recipients) can, however, lead to transient, asymptomatic, and self-limiting viral activation [10] , especially in the urothelium, which harbors latent BK-virus infections in 43% of individuals [11] (Table 1) . Such activation is characterized by the detection of free viral particles in the urine (by electron microscopy or PCR techniques) and intranuclear viral inclusion bearing cells, so-called 'decoy cells' in urine cytology specimens. Polyomavirus (re)activation and the shedding of decoy cells are generally not associated with tissue injury and kidney dysfunction, i.e. a rise in serum creatinine levels, or other symptoms [12] [13] [14] .
Disease caused by polyomaviruses is only seen in patients with pronounced and long-lasting immunosuppression (Table 1) . Productive BK-virus infections and, in particular, BKN have gained considerable interest over the last decade. Our current knowledge of BKN is primarily based on findings made in humans. Thus far, only rare animal studies have been reported describing either incidental findings [15] or 'models of viral nephropathy' that unfortunately only vaguely resemble human disease [16] [17] [18] [19] .
BK-virus nephropathy (BKN)
BK-virus nephropathy affecting a kidney transplant was first described as a single case report by the pathologist Mackenzie in 1978 [20] . In subsequent years during the era of cyclosporine and azathioprine based immunosuppression, BKN was largely 'forgotten' [12, 21] . The clinical scenario changed dramatically in the mid-1990s when new third generation immunosuppressive drugs, specifically, high-dose tacrolimus and mycophenolate-mofetil were introduced into the routine management of kidney transplant recipients worldwide [12, [21] [22] [23] [24] . Interestingly, one of the largest initial series of patients suffering from BKN was reported from the University of Pittsburgh, one of the first transplant centers that had largely replaced cyclosporine with tacrolimus [25] . Recently, Mengel et al. reported a 10-13 times higher odds ratio for BKN in patients under tacrolimus (trough level >8 ng/ml) and (high-dose) mycophenolate-mofetil therapy [26] ; similar findings were reported by Rocha et al. [27] . Risk factors for BKN, however, are still only incompletely understood [6, [27] [28] [29] [30] [31] [32] [33] and BKN has, on occasion, also been reported in centers still using conventional cyclosporine and azathoprine based therapy [34] , or calcineurin inhibitor-free protocols containing sirolimus and mycophenolate-mofetil [35] . Currently, BKN is reported with a prevalence of 1-9% (6.5% at the University of North Carolina in Chapel Hill) in adult and pediatric patients; its incidence rate is rising [26] [27] [28] 30, 34, [36] [37] [38] [39] [40] . BKN is by far the most important infectious complication affecting kidney transplants. It exceeds productive cytomegalovirus (CMV) infections of renal allografts by approximately 50-100 [47] . Polyomavirus nephropathy is nearly always caused by a productive infection with the BK strain. Only a minority of cases (approximately one third) show activation of polyoma-BK-and JC-viruses simultaneously with, as yet, undetermined biological significance [48, 49] . Polyomavirus nephropathies that are only induced by a productive JC or SV40 virus infection are exceptionally rare [50, 51] . BKN is practically never seen in association with a concurrent second viral infection of the kidney. We are only aware of two anecdotal cases, both of which showed dominant activation of either adenovirus [52] or CMV [53] with only focal 'minor' evidence of BKN. In severely immunocompromised transplant (other than kidney) and nontransplant patients, BK viruses can rarely also enter into a replicative cycle in the native kidneys [54] [55] [56] [57] [58] [59] [60] . We have seen two cases of BKN in native kidneys from patients suffering from B-cell lymphomas. Histologic changes induced by productive BK-, JC, or SV40-polyomavirus infections in renal allografts or native kidneys are identical; ancillary techniques such as immunohistochemistry, in situ hybridization, or PCR are required for the identification of viral strains.
BK-virus nephropathy has been diagnosed as early as 6 days and as late as 6 years postgrafting (mean: 380 days) [28, 34] . The exceptional case observed at day 6 postsurgery by Sachdeva, M.S. and colleagues [34] showed high intrarenal BK-virus loads (>2.5 · 10 5 BK copies per 25 000 cell equivalents) typical for BKN (Nickeleit, V., pers. obs.). Depending on the extent of virally induced tubular injury, patients clinically present with varying degrees of allograft dysfunction. Serum creatinine levels vary from normal (early BKN stage A) to markedly increased (late stages with marked injury, BKN stages B and C; Table 2 ) [28, 29, 38, 61] . Systemic signs of an infection (fatigue, fever) are absent (with only one exception) [62] . BKN is typically limited to the transplant, and the failed native kidneys seem to be free of disease [63] . BKvirus associated hemorrhagic cystitis, often seen after bone marrow transplantation, is not a characteristic symptom found in the setting of BKN. Although early observations linked productive infections of BK viruses to the development of ureteral stenosis [64] , a recent series could only detect BK viruses in 8% (2/25) of histologically analyzed necrotic ureters [65] . The pathophysiological Table 2 . Histologic patterns/stages of polyoma-BK-virus nephropathy*. • £25% of biopsy cores involved Stage B2
• >26% and <50% of biopsy cores involved Stage B3
• ‡50% of biopsy cores involved (if interstitial fibrosis and tubular atrophy >50%: stage C) Pattern/stage C (late sclerosing changes)
• Viral activation in cortex and medulla • Interstitial fibrosis and tubular atrophy >50% of biopsy cores*** • Tubular epithelial cell necrosis/lysis and basement membrane denudation (minimal to marked) • Interstitial inflammation** (minimal to marked) *Additional signs of BK-virus activation are always present: (i) Decoy cells in the urine; (ii) detection of BK-virus DNA or RNA in the plasma and urine; (iii) detection of free virions and three dimensional viral aggregates, ''Haufen'', in the urine by negative staining electron microscopy. ** Interstitial inflammation and tubulitis can in some cases mark concurrent tubulo-interstitial cellular rejection; rejection induced changes are not part of this scoring scheme. ***Interstitial fibrosis and tubular atrophy interpreted to be mostly secondary to protracted virally induced tubular injury.
significance of the activation of BK viruses in necrotic ureteral walls is undetermined, i.e. secondary viral activation in areas of injury (role of an innocent by-stander) versus causative effect (role of a driver). Evidence of ureteral stenosis in the setting of BKN is uncommon. A definitive diagnosis of BK-virus-induced nephropathy requires a kidney biopsy, and the detection of characteristic histologic changes.
Morphology of BKN
Two morphologic features define BKN in renal allografts and native kidneys: (i) intranuclear viral inclusion bodies in epithelial cells and (ii) virally induced tubular epithelial cell injury and lysis. BK viruses use the proliferative 'machinery' of the host cells for replication [66] , and the formation of intranuclear viral inclusion bodies in tubular epithelial cells and parietal glomerular epithelial cells is a hallmark of a productive infection [21, 22, 25, 28, 29, 41, 61, 67] . Viral replication ultimately results in the lysis/necrosis of inclusion bearing cells and the denudation of tubular basement membranes. This virally induced type of (acute) tubular injury is a morphologic correlate for the clinically observed kidney dysfunction [12, 21, 28, 29, 41, 61] . Despite marked epithelial damage, however, the tubular basement membranes usually remain intact. They can serve as the structural skeleton for subsequent tubular regeneration once the viral replication ceases. Very rarely, BKN is associated with marked tubular rupture and the formation of large, nonnecrotizing granulomas.
Cytopathic epithelial cell changes and acute virally induced tubular injury typically show a focal distribution pattern, often involving the medulla. Severely damaged tubules containing many inclusion bearing epithelial cells are characteristically located adjacent to normal ducts (Fig. 1) . This observation may reflect the ascending route of viral spread within infected nephrons. Signs of a productive BK-virus infection can also be detected in the transitional cell layer lining the renal pelvis, the ureters and/or the urinary bladder [21] . Viral inclusion bodies in the urothelium, however, are not part of the histologic hallmarks defining BKN as they can also be seen in patients with hemorrhagic cystitis lacking renal tubular involvement or as incidental findings marking asymptomatic viral activation [12, 14, 68, 69] .
In some patients, BKN is associated with focal granular immune deposits along tubular basement membranes (positive staining by immunofluorescence microscopy with various antibodies directed against immunoglobulins and complement factors); this finding is currently of undetermined clinical significance [70] . The complement degradation product C4d, a marker for an antibodymediated alloresponse, is not seen in typical cases of BKN; therefore, its presence indicates BKN and concurrent acute rejection (see below) [28, 61, 71, 72] . Viral replication is not associated with marked tubular expression of MHC-class II (HLA-DR) [41] .
All cases of BKN characteristically show large numbers of polyomavirus inclusion bearing cells in the urine, i.e. so-called decoy cells. The detection of decoy cells serves as an important ancillary diagnostic tool during clinical risk assessment (see below) [12, 13, 22, 28, 31, 41, 61, [73] [74] [75] .
Ancillary diagnostic techniques
Although the histologic changes are characteristic for BKN, they are not pathognomonic as other viral infections caused by Herpes Simplex Virus, Adenovirus, or Cytomegalovirus must be considered in the differential diagnosis [41, 76, 77] . Diagnostic confirmation of BKN is generally achieved by immunohistochemistry (with antibodies directed against the T-antigen -associated with viral replication, or against VP capsid proteins -associated with mature viral particles), in situ hybridization and/or electron microscopy. These techniques are well suited to identify viral families and potentially viral strains if a productive viral infection is already suspected by light microscopy [28, 41, 78] . Their routine diagnostic use as generalized screening tools to 'hunt' for a productive polyomavirus infection, however, is neither helpful nor cost effective [21, 26] . PCR techniques may also be utilized to demonstrate viral DNA or RNA in tissue samples and to confirm the diagnosis of BKN [57, 79, 80] . However, PCR results must be interpreted with caution. Only strong amplification signals of viral DNA (greater than 10 BKvirus copies per cell equivalent), in the setting of histologically or immunohistochemically demonstrable virally induced cytopathic changes, can be used to confirm the diagnosis of BKN and to distinguish clinically significant productive from clinically insignificant latent BK-virus infections [6] [7] [8] 57, 60, 79, 81] . The detection of viral RNA in renal biopsy cores by PCR clearly indicates viral replication. RNA extraction and amplification methods, however, are challenging techniques, susceptible to error, and do not provide additional information exceeding the results obtained with standard immunohistochemistry (such as the detection of the SV40-T antigen) [57, 80] .
Histologic stages/patterns of BKN BK-virus nephropathy can present with different histologic patterns and progress through various stages [15, 21, 28, 29, 32, 41, 61, 73, 82] . Three stages/patterns have recently been defined [32, 61, 67, 73] . They are listed here with slight modifications (Table 2) .
Pattern A (limited/early stage) Signs of viral activation are found in cortical and/or medullary tubular cross-sections (Fig. 1a and b) . Typical for pattern A is the lack of virally induced epithelial cell lysis. Denudation of tubular basement membranes is inconspicuous. Viral activation is characterized by intranuclear viral inclusion bodies that can be lacking on exceptionally rare occasions. In these latter cases, viral activation is only identified by positive intranuclear immunohistochemical or induced epithelial cell lysis, denudation of tubular basement membranes, and interstitial edema ( Fig. 2a and b) . Mononuclear inflammatory cell infiltrates (sometimes containing abundant plasma cells and polymorphonuclear leukocytes) are common, and tubulitis can be observed in areas of viral activation. Interstitial fibrosis and tubular atrophy are minimal to moderate (involving, per definition, <50% of the biopsy cores). Changes classified as pattern B may occur in the renal cortex and medulla and can be subclassified as follows: (i) pattern B1, £25% involvement of the biopsy cores; pattern B2, 26-49% involvement of the biopsy cores; pattern B3, ‡50% involvement of the biopsy cores (virally induced tubular injury and/or inflammation; fibrosis and tubular atrophy are, per definition, less than 50%).
Pattern C (late, sclerosing stage)
Signs of viral replication are associated with tubular epithelial cell injury ( Fig. 3a and b) . Interstitial inflammation can vary from minimal to marked. Fibrosis and tubular atrophy secondary to virally induced injury involve, per definition, more than 50% of the tissue sample. Changes classified as pattern C are frequently most pronounced in the renal cortex but can also be seen in the medulla.
Although the unequivocal classification of the different patterns of BKN may occasionally be challenging because of other concurrent diseases, such as pre-existing donor lesions with interstitial fibrosis or acute or chronic rejection, an attempt to classify BKN should be made as these patterns carry pathophysiological, clinical and prognostic significance.
Stage/pattern A represents the initial phase of BKN with only very focal 'nonlytic' viral activation. It is frequently found in the medulla and likely represents re-activated foci of latent BK-virus infections. Pattern A, in contrast to patterns B and C, is diagnosed early (8.7 months posttransplantation versus 15.9 months respectively) [46] and often responds to therapy with favorable long-term graft function and survival [28, 31, 38, 41, [45] [46] [47] 61, 73] . Resolution of BKN has been observed in up to 78% of patients [46] . As tubular injury in pattern A is very limited, graft function typically remains stable, and the optimal timing of a diagnostic graft biopsy becomes a clinical challenge [28, 41, 46, 61] . BKN pattern A can progress to patterns B or C if productive viral replication spreads and virally induced tubular injury persists over weeks to months (compare Fig. 1 with Fig. 3) . In one series, progression was observed in repeat diagnostic biopsies in 37% of patients initially presenting with pattern A and in 60% presenting with pattern B [82] . Regression from pattern B (in particular B1) to pattern A may be observed during the resolution of BKN; fibrosis and tubular atrophy found in pattern C are irreversible.
The therapeutic goals of BKN in patterns A and B are to limit viral replication and tubular injury, to promote tubular epithelial cell regeneration and to prevent disease progression to pattern C with irreversible scarring (Fig. 3) . BKN-pattern C is typically associated with severe allograft dysfunction or loss [21, 29, 61, 82] .
BK-virus nephropathy patterns A-C are associated with varying degrees of interstitial inflammation. The inflammatory cell infiltrate, especially in pattern B, can represent 'virally induced' interstitial nephritis with polymorphonu- clear leukocytes located adjacent to severely injured tubules (with urine back-leak), abundant plasma cells, mononuclear cells, and tubulitis in foci with viral activation [15, 21, 28, 41, 61, 67, 73] . Cytotoxic T lymphocytes seem to play a role in the containment of BK virus [83] . However, in some cases (especially in pattern A that should, per definition, lack significant inflammation), mononuclear cell infiltrates rich in lymphocytes and a lymphocytic tubulitis can be found representing BKN and concurrent acute allograft rejection [71] . The diagnosis of acute rejection and concurrent BKN is challenging. It carries clinical significance as therapeutic strategies should be adapted and rejection should be treated [28, 31, 41, 45, 61, 71] . Rejection can be more easily diagnosed if transplant endarteritis, transplant glomerulitis, tubulitis in areas without viral activation, tubular expression of MHC-class II (HLA-DR) or C4d along peritubular capillaries are detected [28, 29, 31, 41, 45, 61, 71, 72] . As cases of BKN with marked tubulitis generally fare poorly [73] , unrecognized tubulointerstitial cellular rejection (Banff type I) may potentially contribute to BKN-induced graft demise more frequently than commonly suspected [71, 84] .
The immunohistochemical phenotyping of the inflammatory cells in BKN has shown plasma cell (CD138) as well as B-(CD20) or T-cell (CD3) dominant infiltrates with currently undetermined pathophysiological significance. It is not diagnostically helpful for distinguishing viral nephritis from concurrent acute cellular rejection [85] [86] [87] .
Patient management
Although specific antiviral treatment strategies are still largely undefined [32, 88] , much progress has been made to better assess the risk for BKN, to optimize the timing of a diagnostic graft biopsy (patient screening), and to evaluate the response to therapy (patient monitoring). These strategies result in improved graft survival and also contribute to the reduction of health care costs [28, 31, 32, 41, 45, 67, 89, 90] . Here, we critically review selected management recommendations rendered during the first interdisciplinary conference on polyomavirus-associated nephropathy [32] .
The risk for BKN after kidney transplantation is classified as: (a) level 0 -no risk; (b) level 1 -possible BKN (low risk, additional testing and surveillance are required); (c) level 2 -presumptive BKN (high risk, allograft biopsy and close surveillance are required); (d) level 3 -definitive BKN (biopsy proven viral nephropathy).
The diagnosis of BKN (in renal transplants and native kidneys) must be made in a biopsy specimen, ideally containing two cores of cortex and medulla obtained with a 15-gauge needle (definitive BKN, level 3). As mentioned above, BKN often only focally affects renal tubules and collecting ducts. Thus, foci of productive viral replication may be missed because of sampling errors if: only one biopsy core is taken; the needle size is too small (e.g. 18 gauge); medullary parenchyma is not sampled. Biopsies from cases with BKN consisting of multiple tissue cores showed individual biopsy cylinders with discordant 'BKpositivity' in 37% of cases [73] . In our own biopsy material, 25% of cases showed cytopathic viral changes limited to the renal medulla. Thus, the diagnosis of BKN may be missed in 25-37% of biopsy samples only consisting of one small core of cortex.
In BKN pattern A, renal function can be normal, thereby, obscuring the need for a diagnostic biopsy [28, 38, 41] . To adequately assess the risk for viral nephropathy and to optimize the timing for a biopsy, signs of viral activation can be used for clinical guidance (Table 1 , Fig. 4 ): search of polyomavirus inclusion bearing decoy cells by urine cytology, assessment of free virions in the urine by negative staining electron microscopy, quantitative PCR analyses to measure BK-virus DNA loads in the urine or plasma, or alternatively, quantitative RNA measurements to detect viral RNA in the urine [12, 13, [21] [22] [23] 28, 29, 31, 41, 61, 73, 74, 82, 89, [91] [92] [93] [94] . As the latter technique is susceptible to technical errors, not in common use, and not superior to the widely available detection of decoy cells, it will not be considered further [74] . Signs of viral activation should be integrated into an individual patient risk profile.
Decoy cells
All patients with BKN shed abundant polyomavirus inclusion bearing 'decoy cells' in the urine. They can be easily detected in standard Papanicolaou-stained cytology preparations or -with some expertise -also in the urine sediment by phase contrast microscopy [12, 13, 21, 28, 31, 41, 73, 75, 82, [95] [96] [97] . Polyomavirus inclusion bearing decoy cells are believed to commonly originate from the transitional cell layer and to often contain BK viruses [13, 14, 68, 69, 98] . Although one decoy cell is sufficient to mark the activation of polyomaviruses, in clinical practice an arbitrary threshold level of more than 10 decoy cells per liquid-based cytology preparation (i.e. ThinPrep) has been set to distinguish 'decoy positive' from 'decoy negative' patients [13] . The positive predictive value of a 'positive' decoy cell analysis to predict BKN is 25-30%; however, the negative predictive value is greater than 99%, i.e. 'negative decoy analysis', no viral nephropathy [13, 28, 31, 41, 73, 75] . Any further quantification of decoy cells does not provide additional clinically relevant infor- Figure 4 Schematic algorithm of patient screening and monitoring protocols (modified from Ref. [28] ).
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Polyoma-BK-virus nephropathy mation, i.e. higher numbers of decoy cells do not indicate a higher risk level [28] . As patients developing BKN often turn and remain 'decoy cell positive' months before the initial histologic diagnosis of a viral nephropathy, repeat cytology testing is helpful for proper risk assessment [13, 28, 31, 41, 73] . Decoy cell positive renal allograft recipients fall into risk level 1; they have to be closely monitored at 4-week intervals using repeat cytology examinations and additional quantitative (plasma) PCR tests (Fig. 4) .
Urine electron microscopy
Negative staining electron microscopy on urine samples to search for free virions is a well established technique;
however, it has only been used sporadically in the setting of BKN [23, 40, 94] (Fig. 5a and b) . Free virions are generally found in 'decoy positive' kidney transplant recipients with urine BK-virus load levels greater than 1 · 10 6 copies/ml (measured by PCR) [40, 94] . The shedding of free viral particles follows a dynamic pattern, closely paralleling the excretion of decoy cells. Patients with detectable free virions fall into risk level 1; they have to be closely monitored at 4-week intervals using quantitative (plasma) PCR tests. Analyzing negative staining EM results semi-quantitatively [94] and scoring three-dimensional viral cluster formation (i.e. so-called viral 'Haufen'; Fig. 5b ) may, in the future, add significant clinical information to more precisely predict BKN.
Quantitative PCR analyses on urine and plasma
In 2000, Biel et al. introduced the first quantitative realtime PCR assay for the detection of polyomaviruses in the urine [99] that was soon followed by BK-virus-specific tests [31, 92, 93, 100] . These quantitative assays have vastly improved patient management. The overall positive predictive value of a 'positive quantitative plasma PCR test' to predict BKN is 50% and the negative predictive value is 100% [31] ; plasma viral load levels of greater than 1 · 10 4 copies/ml have a positive predictive value of greater than 80%. Depending on the viral load levels in the plasma and/or urine, patients can be grouped into risk levels 1 or 2. 'Presumptive BKN, risk level 2' is assumed in a patient with BK-virus loads exceeding 1 · 10 4 copies/ml in the plasma and/or 1 · 10 7 copies/ml in the urine [30] [31] [32] 73, 93] . In these patients, an allograft biopsy is indicated to establish a definitive diagnosis. The absence of viremia and/or viruria practically rules out a diagnosis of BKN [32, 93] .
BK viruria and viremia with varying viral load levels are not uncommon in kidney transplant recipients; they most frequently occur during the first year after grafting as asymptomatic events never leading to viral nephropathy (BK viruria: 35-57%, BK viremia: 7-29% of patients) [31, [101] [102] [103] [104] . Approximately 50% of the viremic episodes are transient, one-time phenomena [101, 102] . In some patients, persistent BK viremia can be seen as a prodromal stage of BKN [28, 31, 41] . In daily clinical practice, measurements of plasma or urine BK-virus loads are suited for screening purposes. We and others [105] prefer plasma over urine testing as we feel that the plasma test results are more easily interpretable and critical plasma viral load levels are better defined (also see [94] ).
Although quantitative PCR assays of urine and plasma samples are commonly used in the management of renal transplant recipients, results and recommendations have to be interpreted with caution: (i) Some guidelines are Clinically significant viral load levels remain undetermined. For example, we histologically diagnosed BKN in patients with low plasma load levels (2 · 10 3 copies/ml), whereas in other patients with high plasma loads (3 · 10 4 copies/ml) viral nephropathy was never found even in repeat biopsies. (iv) Critical BK-virus 'threshold levels' only apply at the time of initial diagnostic work-up and not during persistent viral nephropathy to monitor for viral clearance (Fig. 4) . (v) BK viremia should not be automatically interpreted as 'of kidney origin'. It has also been seen in bone marrow transplant recipients, some of them with clinical signs of hemorrhagic cystitis [106, 107] . Thus, viremia can only serve as a general marker of 'BK-virus activation' (Table 1) .
During persistent BKN, the response to therapy (e.g. lowering of immunosuppression, changing drug regimens to cyclosporine and azathioprine, therapeutic attempts with low-dose cidofovir or leflunomide) [32, 100, 105, [108] [109] [110] can be monitored by all of the above-mentioned techniques at 4-week intervals, i.e. monitoring phase [28, 32, 40, 41] . If decoy cells, free virions, and three dimensional viral aggregates (Haufen) disappear from the urine and plasma PCR assays become negative on repeat evaluation, then the histologic resolution of BKN can be assumed (viral clearance from the kidney; Fig. 4 ). BK viruria (evaluated by PCR) often persists after viral clearance from the kidney, although at much lower concentrations than seen at the time of initial diagnosis [40, 93] . Viral resolution typically takes many months. In most studies, a period of >12 weeks of reduced immunosuppression as primary intervention for BKN has been required to mount an antiviral host response and to significantly reduce viral load levels [111] . We have only seen one exceptional case of a patient with biopsy proven BKN (histologic stage A) who cleared the virus from the graft within 3.5 weeks under low-dose immunosuppression and leflunomide therapy. This case, however, is the exception, not the rule.
The best timing and strategies for the prevention and treatment of BKN are currently undetermined [32, 47] . As viral nephropathy seems to be an indicator of intense/ over-immunosuppression [12, 26, 112] and as outcome depends on an early diagnosis [28, 38, 46] , therapeutic intervention may already be initiated at risk level 2 (Fig. 4 ) when patients present with signs of significant viral activation but lack histologic proof of BKN ( [101] , Ginevri et al. reviewed in Ref. [105] ). Viremia (but not viruria) is commonly absent in nontransplant patients and may serve as the earliest indicator of 'over-immunosuppression'. Initial reports from one transplant center suggest that early therapy including low-dose immunosuppression at risk level 2 prevents BKN, and does not increase the risk of acute rejection [101] . However, experience is limited and it remains to be determined whether 'significant viremia' (risk level 2) or alternatively histologic proof of BKN (level 3, definitive BKN in early disease stage A) are the best clinical landmarks for therapeutic intervention. '…Prevention of infection whenever possible with prophylactic or preemptive (…) therapy, and prompt diagnosis and aggressive treatment of microbial invasion when prevention fails…' are the ultimate goals [113] .
If kidney allografts are lost because of progressive BKN, re-transplantation is a good option. Small case series have provided encouraging results: recurrent BKN was only observed in approximately 12% of all repeat allografts [111, 114, 115] .
